Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor–Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint

PURPOSE: Human epidermal growth factor receptor 2 (HER2) positivity is an important prognostic and predictive indicator in breast cancer. HER2 status is determined by immunohistochemistry and fluorescent in situ hybridization (FISH), which are potentially inaccurate techniques as a result of several...

Descripción completa

Detalles Bibliográficos
Autores principales: Myburgh, Ettienne J., Langenhoven, Lizanne, Grant, Kathleen A., van der Merwe, Lize, Kotze, Maritha J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2016
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560457/
https://www.ncbi.nlm.nih.gov/pubmed/28831439
http://dx.doi.org/10.1200/JGO.2016.006072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560457/
https://www.ncbi.nlm.nih.gov/pubmed/28831439
http://dx.doi.org/10.1200/JGO.2016.006072

Ejemplares similares